Medice

Focus: Medice is a German biotech company focused on small molecule therapeutics across nephrology, gastroenterology, and oncology. The company maintains an active pipeline with Phase 2-4 programs but operates with limited public visibility on scale and financials.

Nephrology Gastroenterology Oncology

Profile data last refreshed 2d ago · AI intelligence enriched 1w ago

Open Jobs

About Medice

AI assessmentNot Hiring

No open roles listed right now. Follow Medice to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Integrated Diagnosis and Treatment of Adults With Attention-deficit/Hyperactivity Disorder

Adult Attention-deficit/Hyperactivity Disorder

N/A

Clinical Trials (1)

NCT01615679Integrated Diagnosis and Treatment of Adults With Attention-deficit/Hyperactivity Disorder

N/A

Help build intelligence for Medice

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse pipeline across three therapeutic areas (nephrology, gastroenterology, oncology) provides exposure to multiple indications and clinical stages
Multiple Phase 3 programs (4 total) offer near-term regulatory catalysts and career momentum opportunities
German headquarters in established pharma region with potential for stable, long-term employment in European biotech ecosystem

Watch Out For

Zero active job openings currently listed, suggesting potential hiring freeze or limited growth phase
Sparse public financial data and pipeline transparency limit visibility into company stability and resource allocation
Heavy reliance on repurposed/existing molecules (methylphenidate, nicotinamide, vitamins) rather than novel drug discovery suggests limited innovation upside

Generated by Claude from Medice's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Attentin® in Children and Adolescents With ADHD - A Non-interventional Study

Attention Deficit Hyperactivity Disorder

N/A

Clinical Trials (1)

NCT02801604Attentin® in Children and Adolescents With ADHD - A Non-interventional Study

N/A

Bifidobacterium longum 35624

Irritable Bowel Syndrome

N/A

Clinical Trials (1)

NCT04859075Efficacy and Safety of Alflorex Bei Reizdarm in Patients With Irritable Bowel Syndrome

N/A